Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.75 -12.96% 11.75 748,911 10:47:03
Bid Price Offer Price High Price Low Price Open Price
11.50 12.00 13.50 11.375 13.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -7.24 -4.46 29
Last Trade Time Trade Type Trade Size Trade Price Currency
12:11:34 O 12,000 11.9499 GBX

Futura Medical (FUM) Latest News

More Futura Medical News
Futura Medical Takeover Rumours

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date Time Title Posts
24/2/202009:11FUTURA a winner for 20157,290
05/2/202012:57fum reality28
08/7/201908:08one million2
21/1/201909:54www.bluediamondcondom.com59
02/12/201613:27FUM delivering on sex,pain and rock'n'roll11,414

Add a New Thread

Futura Medical (FUM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:11:3511.9512,0001,433.99O
11:16:2211.7534340.30O
10:54:0512.006,000719.70O
10:50:1312.0024,9182,988.91O
10:46:5611.907,924942.96O
View all Futura Medical trades in real-time

Futura Medical (FUM) Top Chat Posts

DateSubject
24/2/2020
08:20
Futura Medical Daily Update: Futura Medical Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 13.50p.
Futura Medical Plc has a 4 week average price of 8.60p and a 12 week average price of 7.75p.
The 1 year high share price is 49p while the 1 year low share price is currently 7.75p.
There are currently 245,626,926 shares in issue and the average daily traded volume is 1,475,156 shares. The market capitalisation of Futura Medical Plc is £28,861,163.81.
20/2/2020
11:56
bioking: DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY Diurnal (DNL) Market Cap £27 M Price: 31p Upcoming Catalysts: MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 2Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses
19/2/2020
15:08
pdt: It will be interesting to see how the share price moves over the next 18 months. Value Inflection points of two submissions; EU mid year and FDA at some point. Hopefully followed by approvals within 12 months of that. I suspect territory deals will be struck rather than a global partner and that these could come at any time. Although there are other indications all the value seems to attached to ED. Perhaps a steady rise in the share price as peeps realise the value here or leaps as inflection points are met? Time will tell I guess, I am new here but the risk/reward looks attractive.
21/1/2020
12:52
stockstracker: Did Changing Sentiment Drive Futura Medical's (LON:#FUM) Share Price Down A Painful 77%? https://cutt.ly/OrnGK8i
08/1/2020
10:51
ih_116147: The most underpriced and attractive british biotech company with MASSIVE upside potential .Still think this sleeping giant has 10+ bagger upside potential and 2020 could be the year for DNL with all the approvals and partnerships expected during the year .GL Diurnal (DNL) Market Cap £24 M Price: 29p DCF valuation of 202p per share https://www.hardmanandco.com/wp-content/uploads/2019/11/DNL-2019-results-5-November-2019.pdf Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses Presentation hxxps://www.diurnal.co.uk/media/36783/full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf Upcoming Catalysts: US-NDA acceptance for Alkindi in Februry 2020 MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 1Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 $88m market opportunity (Europe and US) for Paediatric AI (inc CAH) $351m market opportunity (Europe and US) for Congenital Adrenal Hyperplasia $2,767m market opportunity (Europe and US) for Adrenal Insufficiency Ceo bought another 25k shares at 30p hxxps://www.ii.co.uk/news/director-dealings-rnsLSE20191216114654_14350421
27/12/2019
13:37
j777j: The shares were trading near 50p a few months earlier,will give you a clue. The valuation was forecast at 140p a share on successful trial results another. The co is actually in a very strong negotiating position right now.No need to spend £10 million on a US Phase 3 trial. The trial has actually produced a larger commercial opportunity. So might be another clue as to why the shares were so mispriced,but the market is the market and LO played a clever game. Money in the bank to enable continued commercial negotiations from a position of great strength. 0ver 30% of the co changed hands below 15p which was where it pretty much gapped lower on the open on dec 10th. The most recent forecasts were for a share price of 60p. Disgruntled former shareholders always the worst.
30/11/2019
08:48
siriusbizness: You know what they say about stats. The Company will present those that show the best results for med2005. That will really set the size of the market available. Either way if only just mild ED and it can be a primary treatment then it’s huge. I am more interested in the funding. Couple of options available. Placing (maybe private) at higher share price as they did post phase 2 study. I like this as it means the Company don’t give too much away too soon. Partnership with up front and milestone payments is the other option. This is what the Company has been looking at for years but really depends on the phase 3 results to get the best deal. Either option sees a much higher share price so sit tight and let’s see.
01/10/2019
11:19
j777j: My own view is the share price could reach Liberum's 60p price target upon news of completion of Phase 3 trials in a few days time. As this will be the most significant milestone in the company's history to date. If the trial results in december are a success the share price could head well over 100p.Liberum reckon 145p. Not long to wait. GLA to all patient holders.
02/3/2018
15:12
j777j: Something for the weekend courtesy Gold dust on lse goldust881,179 posts Potential share price for Futura ? What is the future for Futura's share price. I have detailed below, from info in the results and more particularly from the webcast presentations what news Futura expects to announce during 2018, of which there is quite a lot that will affect the share price. MED2000-Securing of major commercial deal. CSD500-Reasignment of Rights for most of Europe and USA CSD500-Launch in 6 more countries and possibly up to 13. TPR100 & TIB200 -securing of further deals in USA/Europe. So what about the share price. Clearly there is massive potential if all the products end up all on sale at once but leading up to that point I think that announcements of each of the above this year will increase the share price as each one will confirm that progress is being made, some more than others. Clearly with any deal being announced one can expect upfront deal fees which can be substantial and this is what Futura expect as they stated at the results seminar they have no need to raise further cash. Looking at other company deals in these sectors the total upfront fees could easily be in the ?25-40 million range. So what could Futura be worth in a couple of years time. From global sales figures provided by Futura we have the following potential for Futura's market share and earnings. MED 2000 ($1 billion per annum)= ?800 million say @5% royalty is ?40 million pa TPR100 & TIB200 (1/2 billion per annum)=?400 million say @5% royalty is ?20 million pa CSD500 @10% market share of a $6billion pa market is $600 million=?450 million @ 5% royalty rate is ?9 million per annum. That totals to ?69 million per annum. That's the potential. So with an income of that size with minimal overheads the company on a p/e of 10 % would be valued at ?690 million or ?5.56 per share Current company value @ 47p today is appx 57million So the potential is 10 times the current share price. With lots of news this year we could easily see the share price double up with the newsflow and a big bucks rise coming after the current MED 2000 trial results due shortly. News may come at any time so it's a buy at this price now in my view with results due out on 14th March. If any of one of these major deals comes of the share price would double.. Clearly another investor who has done the maths and sees a ten bagger from here.
07/6/2017
08:33
mikethebike4: james 'There will also be many new launches of the condom within the next 6 months which will help with the profile and see FUM Share price rocket....so the next 6 months are most interesting and the best time to be in here. - I have seen this written so many times over the last few years - I will be so shocked when it actually happens I will probably climax on the spot without the aid of Blue Diamond ! - 18 months product is already available from TTK in Asia - why they did not submit for regulatory approval at the same time in Europe I do not know - however I am expecting an announcement by the BoD so that the AGM is not a 'damp squib' MTB4
06/6/2017
21:59
jamesd888: There will also be many new launches of the condom within the next 6 months which will help with the profile and see FUM Share price rocket....so the next 6 months are most interesting and the best time to be in here.
Futura Medical share price data is direct from the London Stock Exchange
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200224 12:26:45